Bindbridge
Cambridge, UK· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing small molecule drugs targeting difficult protein-protein interactions in cancer.
Oncology
Technology Platform
A structure-based drug discovery platform specifically engineered to design small molecules that modulate intracellular protein-protein interactions.
Opportunities
Potential to create first-in-class therapies for validated oncology targets that lack small molecule inhibitors.
Risk Factors
High technical risk associated with successfully drugging challenging PPIs and demonstrating clinical efficacy.
Competitive Landscape
Operates in a competitive but cutting-edge field alongside other biotechs targeting 'undruggable' PPIs, such as Ideaya Biosciences and Frontier Medicines.